Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Treatment of Prader–Willi syndrome with growth hormone: merits and limits of postmarketing surveillance studies

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 88–89 (2007)Cite this article

boxed-textCraig ME et al. (2006) Growth hormone treatment and adverse events in Prader–Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 65: 178–185

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Carrel AL et al. (2002) Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 87: 1581–1585

    Article  CAS  Google Scholar 

  2. Eiholzer U et al. (1998) Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 157: 368–377

    Article  CAS  Google Scholar 

  3. Haqq AM et al. (2003) Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 88: 2206–2212

    Article  CAS  Google Scholar 

  4. Schrander-Stumpel CT et al. (2004) Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet 124: 333–338

    Article  Google Scholar 

  5. Eiholzer U (2005) Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res 63: 33–39

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Ian Newman, Editor, Nature Clinical Practice.

Author information

Author notes

  1. University of Wisconsin, Children's Hospital, Department of Pediatrics, H4/448 CSC-Pediatrics, 600 Highland Avenue, Madison, WI 53792-4108, USA dballen@wisc.edu

Authors and Affiliations

  1. DB Allen is a Professor of Pediatrics and the Director of Endocrinology and Residency Training, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.,

    David B Allen

Authors
  1. David B Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received research grant support from Pfizer Inc. and Genentech Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allen, D. Treatment of Prader–Willi syndrome with growth hormone: merits and limits of postmarketing surveillance studies. Nat Rev Endocrinol 3, 88–89 (2007). https://doi.org/10.1038/ncpendmet0393

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0393

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing